No abstract

Background: Topical silicone gel has shown promise in the treatment of hypertrophic and keloid scars. However, its mechanism of action remains undetermined. Objective: To investigate whether the presence of silicone alters the secretion of basic fibroblast growth factor (bFGF), a key cytokine involved in the scar formation process. Design: Serum-free fibroblast cell cultures were established from normal, keloid, and fetal skin, which heals without scarring, and exposed to silicone gel. Serial cell counts were performed, and supernatants were collected for bFGF quantification by enzyme-linked immunosorbent assay at 4, 24, 72, and 120 hours. Results: Growth curves were similar and no statistically significant differences in population doubling times were observed between treated and untreated specimens. Statistically significant differences in bFGF levels between treated and untreated normal fibroblasts were observed at 24, 72, and 120 hours after cell culture initiation. Differences in bFGF levels between treated and untreated fetal fibroblasts that approached statistical significance were observed at 72 and 120 hours. Conclusions: These results suggest that silicone gel is responsible for increased bFGF levels in normal and fetal dermal fibroblasts. We postulate that silicone gel treats and prevents hypertrophic scar tissue, which contains histologically normal fibroblasts, by modulating expression of growth factors such as bFGF. Our data support the hypothesis that substances that favorably influence wound healing do so by correcting a deficiency or overabundance of the growth factors that orchestrate the tissue repair process.

Collagen tubules filled with BDNF-enriched collagen gel appear to be at least as good as autologous nerve grafts for bridging short facial nerve gaps. Larger experimental studies are warranted to determine if clinical trials are justified.

The purpose of this study was to update our in vitro serum-free keloid fibroblast (KF) model by use of commercially available media. Prior evaluations of fibroblast characteristics in vitro, especially that of growth factor measurement, have been confounded by the presence of serum-containing media. KFs were obtained from patients undergoing facial keloid removal. The 4 commercially available serum-free media evaluated were AIM-V (Gibco, Grand Island, NY), Fibroblast Growth Medium (FGM; Clonetics, San Diego, CA), HB GRO (Irvine Scientific, Santa Ana, CA), and UltraCULTURE (BioWhittaker Inc, Walkersville, MD). The main outcome measures were sustained KF growth and viability as compared with serum-based models. The KFs in UltraCULTURE had a higher viability but did not grow as well as in FGM. The KFs in HB GRO and AIM-V demonstrated significantly decreased viability. Because of FGM's satisfactory proliferative support and viability comparable with serum-based medium, it is recommended for the in vitro propagation of keloid-producing fibroblasts.

In this experimental model of a solid murine sarcoma, allogeneic blood transfusion was associated with an increased rate of tumor growth compared with syngeneic and autologous blood transfusion, likely reflecting immunomodulatory effects incurred by the introduction of major histocompatibility complex-incompatible antigens.